Posted by Michael Wonder on 20 Sep 2025
Health Canada approves Celltrion’s Stoboclo and Osenvelt (CT-P41), denosumab biosimilars for the treatment of all indications approved for the reference products, Prolia and Xgeva, respectively
18 September 2025 - The approval is based on the totality of evidence including results from a Phase III clinical trial in postmenopausal women with osteoporosis.
Celltrion today announced that Health Canada has approved Stoboclo and Osenvelt (CT-P41), biosimilars referencing Prolia and Xgeva, respectively for all indications of reference products.
